Hussein A. Abbas
YOU?
Author Swipe
View article: Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia Open
View article: Advancing Intelligent Fault Diagnosis Through Enhanced Mechanisms in Transfer Learning
Advancing Intelligent Fault Diagnosis Through Enhanced Mechanisms in Transfer Learning Open
Intelligent Fault Diagnosis (IFD) systems are integral to predictive maintenance and real-time monitoring but often encounter challenges such as data scarcity, non-linearity, and changing operational conditions. To address these challenges…
View article: A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias Open
View article: Supplementary Figures from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Supplementary Figures from Single-Cell Profiling of CD8<sup>+</sup> T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion Open
All Supplementary Figures
View article: Figure S3 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Figure S3 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes Open
Figure S3. Flow-cytometry gating strategy. CD, cluster of differentiation, Treg, regulatory T cell
View article: Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Table S8 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes Open
Table S8. Genes used for gene set analysis
View article: Table S1-7 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes
Table S1-7 from Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes Open
Table S1. Baseline characteristics of patients Table S2-S7. The 40 most statistically significant differential expression results
View article: Integrating AI-Generated Materials in EFL: Institutional Dynamics, Teacher Productivity, and Shifts in Instructional Practices in Dir Lower, Pakistan
Integrating AI-Generated Materials in EFL: Institutional Dynamics, Teacher Productivity, and Shifts in Instructional Practices in Dir Lower, Pakistan Open
This study investigates the integration of AI-generated materials in English as a Foreign Language (EFL) classroom, focusing on their impact on teacher productivity and instructional practices. Using a mixed-methods approach, data were col…
View article: Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML)
Macrophage-secreted Pyrimidine Metabolites Confer Chemotherapy Resistance in Acute Myeloid Leukemia (AML) Open
The tumor microenvironment (TME) programs cancer cells to influence therapeutic responses. Macrophages residing in TME switch from pro-phagocytic to tumor-promoting and immunosuppressive phenotypes as cancer develops. While these pro-tumor…
View article: A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia
A Phase II study of azacitidine, venetoclax, and gilteritinib for newly diagnosed adverse risk FLT3-wild type acute myeloid leukemia Open
Introduction: Outcomes of patients (pts) with newly diagnosed (ND) acute myeloid leukemia (AML) and adverse-risk cytomolecular features, including TP53 mutations (mut), and those with previously treated antecedent myeloid neoplasm (referre…
View article: Integrative Spatial Multi-Omics Reveal Niche-Specific Inflammatory Signaling and Differentiation Hierarchies in Acute Myeloid Leukemia
Integrative Spatial Multi-Omics Reveal Niche-Specific Inflammatory Signaling and Differentiation Hierarchies in Acute Myeloid Leukemia Open
View article: 1083 Structure-guided design and repertoire clustering of T cell receptors targeting an AML neoantigen
1083 Structure-guided design and repertoire clustering of T cell receptors targeting an AML neoantigen Open
View article: The Dynamics of Hysteria and Power in Arthur Miller’s The Crucible: A Sociological Perspective
The Dynamics of Hysteria and Power in Arthur Miller’s The Crucible: A Sociological Perspective Open
This paper explores how hysteria is used as a tool of power in Arthur Miller’s The Crucible (1953), focusing on how fear is created and used within a strict religious society to control people and silence opposition. Using a qualitative ap…
View article: Outcomes of patients with newly diagnosed acute myeloid leukemia with <i>FLT3</i>‐tyrosine kinase domain mutations: Prognostic implications of <i>NPM1</i> co‐mutation
Outcomes of patients with newly diagnosed acute myeloid leukemia with <i>FLT3</i>‐tyrosine kinase domain mutations: Prognostic implications of <i>NPM1</i> co‐mutation Open
Background The prognostic impact of Fms‐like tyrosine kinase 3 ( FLT3 )‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts o…
View article: Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia
Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia Open
Background Octa‐nonagenarians with acute myeloid leukemia (AML) represent a high‐risk group due to frequently poor performance status, adverse genomics (e.g., TP53 mutations, complex karyotype), a high incidence of secondary AML, and inabi…
View article: Challenging Societal Boundaries: A Critical Study of Female Self-Actualization in Amber Reeves’ <i>A Lady and Her Husband</i>
Challenging Societal Boundaries: A Critical Study of Female Self-Actualization in Amber Reeves’ <i>A Lady and Her Husband</i> Open
This study explores the psychological and social causes of low self-esteem in women and examines the process through which they attain self-realization and self-actualization. The problem is embedded in socially constructed gender roles th…
View article: An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance
An Isoform-Specific RUNX1C–BTG2 Axis Governs AML Quiescence and Chemoresistance Open
Aberrant levels or structures of RNA isoforms are a hallmark of many cancers, including acute myeloid leukemia (AML), yet their role in AML chemoresistance remains unclear. We conducted a paired analysis of RNA isoform changes in patients …
View article: Supplementary Table S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics of patients in the frontline cohort who underwent allogeneic hematopoietic stem cell transplantation
View article: Supplementary Figure S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Study Treatment Schema
View article: Supplementary Figure S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of patients treated in the frontline cohort, stratified by TP53 status
View article: Supplementary Figure S7 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S7 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) patients in the relapsed/refractory and treated secondary AML cohort stratified by prior venetoclax exposure
View article: Supplementary Figure S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of transplanted patients in the frontline cohort
View article: Supplementary Figure S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of patients in the relapsed/refractory and treated secondary AML cohort
View article: Supplementary Figure S8 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S8 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Quality control metrics of scRNA profiling across all cell types identified
View article: Supplementary Table S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics and outcomes of patients with post-MPN AML
View article: Supplementary Figure S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of transplanted patients with TP53mut in the frontline cohort
View article: Supplementary Figure S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Response rates in the relapsed/refractory and treated-secondary AML cohort
View article: Supplementary Figure S10 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S10 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Distinct phenotypes in microenvironment correlated to response
View article: Supplementary Protocol S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Protocol S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Clinical Trial Protocol
View article: Supplementary Table S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics of scRNAseq patient cohort